Related Experiment Video

Updated: May 30, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K

EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway

Naixiong Peng1, Yuefeng Cai1, Dong Chen1

  • 1Department of Urology, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.

Oncology Research
|January 27, 2025
PubMed
Abstract

Insights

Early growth response factor 1 (EGR1) is decreased in clear cell renal cell carcinoma (ccRCC). Overexpressing EGR1 inhibits ccRCC progression and may offer a new therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Clear cell renal cell carcinoma (ccRCC) lacks targeted therapies.
  • The role of early growth response factor 1 (EGR1) in ccRCC is not well understood.

Purpose of the Study:

  • To investigate the role of EGR1 in ccRCC development and progression.
  • To explore EGR1 as a potential therapeutic target for ccRCC.

Main Methods:

  • Utilized The Cancer Genome Atlas (TCGA) database for EGR1 expression analysis.
  • Performed immunohistochemistry on 55 ccRCC tissues.
  • Conducted gain-of-function assays and Western blot analysis to assess EGR1's biological functions and downstream targets.

Main Results:

  • EGR1 expression was decreased in ccRCC tissues and correlated with advanced TNM stage, metastasis, and poor prognosis.
  • Overexpression of EGR1 inhibited tumor growth, colony formation, motility, and invasion in vitro and in vivo.
  • EGR1 regulates the expression of MMP-2, MMP-9, E-cadherin, and MAPK15, impacting ccRCC cell behavior.

Conclusions:

  • EGR1 plays a tumor-suppressive role in ccRCC.
  • The EGR1/MAPK15 axis presents a potential therapeutic strategy for ccRCC treatment.
Keywords:
Clear cell renal carcinoma (ccRCC)Early growth response factor 1 (EGR1)MigrationMitogen-activated protein kinase 15 (MAPK15)Proliferation

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

8.8K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K